Publication: Bromodeoxyuridine (BrdU)-label-retaining cells in mouse terminal bronchioles
Authors
Kameyama, Hiroki ; Kudoh, Shinji ; Udaka, Naoko ; Kagayama, Motoko ; Hassan, Wael ; Hasegawa, Kohki ; Niimori-Kita, Kanako Niimori-Kita ; Ito, Takaaki
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Adult male mice were continuously treated
with bromodeoxyuridine (BrdU) for 1, 2, or 4 weeks by
an osmotic pump. To detect BrdU-label-retaining cells
(LRCs), putative progenitor/stem cells, other animals
were continuously treated with BrdU for 2 weeks, and
were then kept without any treatments for 2, 6, or 18
months. The lungs were fixed with 4% paraformaldehyde,
and were paraffin-embedded. We
observed terminal bronchioles with BrdU immunostaining
alone or with BrdU immunostaining
accompanying immunostaining for Clara cell secretory
protein (CCSP), forkhead box protein J1 (FoxJ1), or
calcitonin gene-related peptide (CGRP).
The average incidences of BrdU-incorporated cells
in the terminal bronchioles after 1, 2, and 4 weeks of
continuous BrdU infusion were 6.2%, 11.9%, and
23.1%, respectively. Most BrdU-incorporated cells in
these periods were CCSP-immunoreactive (91.7%,
91.3%, and 88.2%, respectively), which means
progenitor function of Clara cells. FoxJ1-immunoreactive
BrdU-incorporated cells were fewer (5.4%,
3.0%, 2.7%, respectively). The average incidences of
BrdU-LRCs in the terminal bronchioles after 2, 6, and
18 months were 7.2%, 4.3, and 2.7%, respectively. Most
BrdU-LRCs were CCSP-immunoreactive (91.0%,
92.7%, and 89.6%, respectively), and FoxJ1-
immunoreactive BrdU-LRCs were fewer (6.0%, 5.7%,
and 2.1%, respectively). CGRP-positive BrdUincorporated
cells were occasional. CGRP-positive
BrdU-LRCs were detected in 17.6% of neuroepithelial
bodies (NEBs) at 2 months, but disappeared at 6 months.
BrdU-positive stem cell candidates, which locate at the
brochiolo-alveolar duct junction or cover NEB, were few
throughout this study.
In conclusion, in the lungs treated only with BrdU,
CCSP-immunoreactive cells are important to maintain
homeostasis in the terminal bronchiolar epithelium.
publication.page.subject
Citation
Histology and Histopathology, vol. 29, nº 5, (2014)
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.